Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms
HIV Medicine · 2023
DOI: 10.1111/hiv.13519 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2023. Verfasst von David Burger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: HIV Infections, Lower Urinary Tract Symptoms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Lower urinary tract symptoms (LUTS) are becoming more prevalent in the ageing population of males living with HIV. Drugs to treat LUTS are known for both their potential role as victims in drug–drug interactions (DDIs) and their side effects. We aimed to evaluate the current use of drugs to treat LUTS and to assess potential DDIs in our cohort of adult males living with HIV.
Design
This was a retrospective review of pharmacy records.
Methods
We recorded the combination antiretroviral therapy (cART) regimen and any use of drugs to treat LUTS (anatomical therapeutic chemical codes G04CA/CB/CX and G04BD). Potential DDIs were assessed using the interaction checker developed by the University of Liverpool ( https://www.hiv-druginteractions.org/checker ).
Results
A total of 411 adult males living with HIV were included in this analysis. The median (interquartile range [IQR]) age was 53 (41–62) years. Nineteen (4.6%) patients used one or more drugs to treat LUTS. As expected, older patients were more likely to be receiving treatment for LUTS: Q1 (20–40 years) = 0%; Q2 (41–52 years) = 2%; Q3 (53–61 years) = 7%; Q4 (62–79 years) = 10%. Seven potential DDIs between cART and LUTS treatment were noted in six of the 19 (32%) patients. Following medication reviews of these six patients, the following interventions were proposed: evaluate safe use of alpha‐blocker ( n = 4), change in cART ( n = 2), and dose reduction of the anticholinergic agent ( n = 1).
Conclusion
Treatment for LUTS coincided with cART in 7%–10% of patients aged above the median age of 53 years in our cohort. Improvements in DDI management appeared to be possible in this growing cohort of males living with HIV and with LUTS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
- Global DDI Solutions, Utrecht, The Netherlands.
- Department of Pharmacy, OLVG Hospital, Amsterdam, The Netherlands.
- Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Geriatrics, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: David Burger, Frank d'Ancona, David Jansen
Zitieren
APA
Burger, D., Oosterhof, P., Grintjes, K., Marneef-Pietersma, M., d'Ancona, F., Zhu, X., Keijmel, S., Richel, O., van Crevel, R., & Jansen, D. (2023). Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms. HIV Medicine. https://doi.org/10.1111/hiv.13519
Vancouver
Burger D, Oosterhof P, Grintjes K, Marneef-Pietersma M, d'Ancona F, Zhu X, et al. Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms. HIV Medicine. 2023. doi:10.1111/hiv.13519
BibTeX
@article{Burger2023,
author = {Burger, David and Oosterhof, Piter and Grintjes, Karin and Marneef-Pietersma, Manon and d'Ancona, Frank and Zhu, Xiaoye and Keijmel, Stephan and Richel, Olivier and van Crevel, Reinout and Jansen, David},
title = {Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms},
journal = {HIV Medicine},
year = {2023},
doi = {10.1111/hiv.13519}
}
EUVIMED